SUJAY KANGO - 21 Sep 2021 Form 4 Insider Report for ACCELERON PHARMA INC

Role
EVP, Chief Commercial Officer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
Issuer symbol
N/A
Transactions as of
21 Sep 2021
Net transactions value
-$547,100
Form type
4
Filing time
22 Sep 2021, 17:56:44 UTC
Previous filing
08 Jun 2021
Next filing
27 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $203,050 +5,000 +27% $40.61 23,509 21 Sep 2021 Direct F1
transaction XLRN Common Stock Sale $750,150 -5,000 -21% $150.03 18,509 21 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5,000 -14% $0.000000 30,000 21 Sep 2021 Common Stock 5,000 $40.61 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.45 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.